- Home
- NINE vs RLYB Comparison
NINE vs RLYB Comparison
Compare NINE & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NINE
- RLYB
- Stock Information
- Founded
- NINE 2011
- RLYB 2018
- Country
- NINE United States
- RLYB United States
- Employees
- NINE N/A
- RLYB N/A
- Industry
- NINE Oilfield Services/Equipment
- RLYB Biotechnology: Pharmaceutical Preparations
- Sector
- NINE Energy
- RLYB Health Care
- Exchange
- NINE Nasdaq
- RLYB Nasdaq
- Market Cap
- NINE 30.7M
- RLYB 13.3M
- IPO Year
- NINE 2018
- RLYB 2021
- Fundamental
- Price
- NINE $0.67
- RLYB $0.31
- Analyst Decision
- NINE
- RLYB Hold
- Analyst Count
- NINE 0
- RLYB 4
- Target Price
- NINE N/A
- RLYB $15.00
- AVG Volume (30 Days)
- NINE 654.9K
- RLYB 93.6K
- Earning Date
- NINE 05-07-2025
- RLYB 05-08-2025
- Dividend Yield
- NINE N/A
- RLYB N/A
- EPS Growth
- NINE N/A
- RLYB N/A
- EPS
- NINE N/A
- RLYB N/A
- Revenue
- NINE $562,450,000.00
- RLYB $848,000.00
- Revenue This Year
- NINE $10.08
- RLYB N/A
- Revenue Next Year
- NINE $2.01
- RLYB N/A
- P/E Ratio
- NINE N/A
- RLYB N/A
- Revenue Growth
- NINE N/A
- RLYB N/A
- 52 Week Low
- NINE $0.60
- RLYB $0.22
- 52 Week High
- NINE $2.07
- RLYB $2.00
- Technical
- Relative Strength Index (RSI)
- NINE 36.18
- RLYB 39.28
- Support Level
- NINE $0.60
- RLYB $0.29
- Resistance Level
- NINE $0.91
- RLYB $0.33
- Average True Range (ATR)
- NINE 0.07
- RLYB 0.02
- MACD
- NINE -0.00
- RLYB 0.02
- Stochastic Oscillator
- NINE 24.22
- RLYB 62.66
About NINE Nine Energy Service Inc.
Nine Energy Service Inc is a North American onshore completion and production services provider. It targets unconventional oil and gas resource development. It operates in one segment, Completion Solutions. The Completion Solutions segment offers cementing services; completion tools, including liner hangers and accessories, frac sleeves, fully composite frac plugs, and specialty open hole float equipment and centralizers and other services. It operates in the U.S, Canada, and other countries where majority of the revenue is generated from the United States.
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.